Adicet Bio Advances Phase 1 Trial for Autoimmune Treatment, Analysts Predict 634.93% Upside

Adicet Bio has progressed in its Phase 1 trial for autoimmune treatment, administering the initial dose to a patient with systemic sclerosis. Analysts forecast an average target price of $6.00, with an upside of 634.93% from the current price of $0.82. The consensus recommendation from 7 brokerage firms is 1.9, indicating an "Outperform" status.

Adicet Bio, Inc. (Nasdaq: ACET) has made significant progress in its Phase 1 clinical trial for autoimmune treatments, marking a key milestone with the first systemic sclerosis (SSc) patient dosed in the ongoing study of ADI-001. The company announced this development on July 24, 2025 [1].

ADI-001, an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting B-cells via an anti-CD20 CAR, is being evaluated for the treatment of various autoimmune diseases. The Phase 1 trial is enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE), SSc, IIM, SPS, and AAV. The trial has four separate arms, with each arm focusing on a specific autoimmune disease [1].

Analysts have responded positively to this development. They forecast an average target price of $6.00, with an upside of 634.93% from the current price of $0.82. The consensus recommendation from seven brokerage firms is 1.9, indicating an "Outperform" status [2].

Julie Maltzman, M.D., Chief Medical Officer of Adicet Bio, expressed optimism about the trial's progress and the potential of ADI-001 to offer transformative benefits for several autoimmune diseases, including SSc. Preliminary clinical data from the trial is expected in the second half of 2025 [1].

Adicet Bio is a clinical stage biotechnology company focusing on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company aims to advance a pipeline of "off-the-shelf" gamma delta T cells engineered with CARs to facilitate durable activity in patients [1].

References:
[1] https://www.morningstar.com/news/business-wire/20250724025385/adicet-bio-announces-first-systemic-sclerosis-ssc-patient-dosed-in-ongoing-phase-1-clinical-trial-of-adi-001-in-autoimmune-diseases
[2] https://investingnews.com/adicet-bio-announces-first-systemic-sclerosis-patient-dosed-in-ongoing-phase-1-clinical-trial-of-adi-001-in-autoimmune-diseases/